Emerging Trends in Biotech, Medtech & Healthcare Investments
Wednesday, May 25, 2016, 6:30pm 9:00pm, Breakthrough Theatre
Financing for the life sciences and healthcare industry is poised to remain robust in the years ahead. Where will the money flow? In this panel discussion, we bring together leading experts from venture capital, private equity and healthcare consulting. Join us for a lively discussion on which areas of innovation are attracting the most funding and what’s coming next.
6.30 - 7.00pm Registration
7.00 - 7.05pm Introduction to BCS and Partners
7.05 - 8.05pm Speaker Introduction & Panel discussion
8.05 - 9.00pm Networking reception with light refreshments
Dr. Kenneth D. Noonan, Ph.D.
CEO, Lightstone Singapore Pte. Ltd.
Ken is currently CEO of Lightstone Singapore Pte. Ltd., an early stage venture fund focused on life science technologies originating in Singapore. He has over 35 years of experience in global life science markets, including pharmaceuticals, devices, diagnostics and research products. Since 2000 Ken was a Venture Partner at Advanced Technology Ventures, a predecessor fund to Lightstone.
Previously, Ken was a senior partner and head of the European Life Sciences practice at L.E.K. Consulting LLP. In his life science consulting career, he has served as Head of European Life Sciences Practice at The Wilkerson Group, as well as Head of European Biopharmaceuticals Practice at Booz Allen & Hamilton.
Ken has been a member of the Board of Directors of public and private life science companies in both the U.S. and Europe, including Intercept Pharmaceuticals Inc., Kailos Genetics and Orchid Biosciences.
Ken holds a PhD in Biochemistry from Princeton University and a Biology degree from St. Joseph’s University.
Dr. Lincoln Chee
Managing Director, Vertex Healthcare Venture Capitals
Lincoln has over 25 years of experience in healthcare as a surgeon, executive and investor. Lincoln is currently on the Board of Holaira, Visterra and Sensimed. Notable past investments include Twelve (acquired by Medtronic), Arana Therapeutics (acquired by Cephalon), Biosensors International (IPO) and Phoenix Hospital Group (IPO).
Prior to joining Vertex, Lincoln served as CEO and Board Member of Quality Healthcare, Hong Kong’s first publicly listed healthcare company. He led the growth and eventual buyout by Fortis Group in 2010. In 2009, Lincoln was selected as Outstanding Entrepreneur of HK. He also held committee positions with Hong Kong Government Food and Health Bureau on e-health Records and Primary Care Delivery Models and an advisory member of Hong Kong Trade and Development Council. Since 2013, Lincoln has been an operating partner advisor for Advent International in healthcare.
Lincoln holds a MBBS from the National University of Singapore. He is a Fellow of the Royal College of Surgeons Edinburgh and a Fellow Academy of Medicine Singapore in Otorhinolaryngology Head & Neck Surgery.
Ms. Anne Kim So Min
Director, Heritas Helios Investments Pte. Ltd.
(IMC Pan Asia Alliance Group)
Anne Kim is an Investment Director of Heritas Helios Investments (an investment management fund of IMC Pan Asia Alliance), focusing on the healthcare sector across Asia. Anne has more than 10 years of experience in investments, capital markets transactions and mergers & acquisitions in the global and Asian healthcare sector.
Anne started her career with J.P. Morgan Healthcare Investment Banking and UBS Healthcare Investment Research in New York and San Francisco. She was also a venture capital investor in biotechnology and medical devices with Investor Growth Capital in New York and Hong Kong. Anne was a founding member of Quadria Capital, a pan-Asian healthcare private equity fund focused on South and Southeast Asia.
Anne is currently a Board Member of the Limited Partner Advisory Committee of Quadria Capital and a Board Member of Tsao Foundation, a non-profit focused on eldercare.
Anne has dual degrees in Biomedical Sciences from the University of Pennsylvania School of Engineering and Economics (Finance) from the Wharton School. Anne is also an alumna of the Harvard Business School.
Mr. Fabio La Mola
Senior Principal, IMS Health, APAC
Fabio’s current role is Senior Principal, and he leads the Strategy Portfolio Assessment Center of Excellence (CoE) at IMS Health. In this role, he is driving client engagements in market entry, growth strategy, M&A screening, private equity diligence and operating model optimization.
Fabio has extensive experience in consulting and life sciences, totaling 16 years. Prior to joining IMS Health, he worked as Principal at L.E.K Consulting and Manager at ZS Associates. Fabio successfully led projects serving both multinational companies (MNCs) and local companies alike on private equity and their portfolio companies within pharma, medical devices and other sectors across Asia Pacific, EMEA, US and China.
Fabio’s expert capabilities include, but are not limited to growth strategies in emerging markets, new products launches, competitive positioning, portfolio complexity reduction, supply chain, process and organizational excellence, especially for medical devices, diagnostics and healthcare services.
Fabio holds a MBA from the Kellogg School of Management at Northwestern University and a Bachelor of Arts in International Business from Bocconi University, Italy.